Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SusmedTSE:4263 -0.94%55 3-Year EBITDA Growth Rate is -93.90% as of Mar. 2026. GuruFocus rates TSE:4263 with a GF Score™ of 55/100 and a GF Value™ of 円903.11 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Susmed ranks worse than 99.05% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -93.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -2.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Susmed was 36.80% per year. The lowest was -93.90% per year. And the median was 1.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Susmed 3-Year EBITDA Growth Rate Related Terms
TSE:4263 vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Susmed's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Susmed 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Susmed's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Susmed's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -93.90% mean?
Susmed (TSE:4263) has a 3-Year EBITDA Growth Rate of -93.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Susmed and its competitors. According to the industry distribution chart, Susmed ranks #521 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 99%.
Is Susmed's 3-Year EBITDA Growth Rate too high?
Susmed's current 3-Year EBITDA Growth Rate is -93.90%. Based on the distribution chart, Susmed ranks #521 out of 526 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Susmed has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Susmed's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #521 out of 526 companies for 3-Year EBITDA Growth Rate. This places Susmed in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Susmed and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current 3-Year EBITDA Growth Rate is -93.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Possible Value Trap. The stock's GF Value™ is 円903.11, compared to a current price of 円422.00 — trading 53.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -93.90%. Susmed's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Susmed (TSE:4263), the current 3-Year EBITDA Growth Rate is -93.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円422.00 is trading 53.3% below its estimated GF Value™ of 円903.11.
GuruFocus considers Susmed to be Possible Value Trap.
Key valuation signals for TSE:4263:
3-Year EBITDA Growth Rate: -93.90%
GF Value™: 円903.11 vs. price of 円422.00 (53.3% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
55GF Score
Get the complete analysis for TSE:4263
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
